IHH Healthcare's Earnings Outlook Remains Attractive -- Market Talk

Dow Jones

Dec 30, 2024

0112 GMT - IHH Healthcare's earnings outlook may remain attractive amid rising demand and revenue intensity, particularly in the Indian and Malaysian markets, as key growth drivers, Maybank IB analysts Yin Shao Yang and Nur Natasha Ariza say in a note. Despite the stock's over 20% year-to-date share price gains, valuations indicate potential for a re-rating as IHH pursues both organic and strategic inorganic expansion, they add. The analysts project a 13% compound annual growth rate in three-year forward revenue and Ebitda for IHH. Maybank resumes coverage on IHH with a buy rating and raises its target price to MYR7.97 from MYR7.13. Shares are unchanged at MYR7.23. (yingxian.wong@wsj.com)

(END) Dow Jones Newswires

December 29, 2024 20:12 ET (01:12 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2495551013"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2495551013\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2495551013?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-30 09:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2495551013","market":"nz","top_or_hot":-1,"title":"IHH Healthcare's Earnings Outlook Remains Attractive -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0112 GMT - IHH Healthcare's earnings outlook may remain attractive amid rising demand and revenue intensity, particularly in the Indian and Malaysian markets, as key growth drivers, Maybank IB analysts Yin Shao Yang and Nur Natasha Ariza say in a note. Despite the stock's over 20% year-to-date share price gains, valuations indicate potential for a re-rating as IHH pursues both organic and strategic inorganic expansion, they add. The analysts project a 13% compound annual growth rate in three-year forward revenue and Ebitda for IHH. Maybank resumes coverage on IHH with a buy rating and raises its target price to MYR7.97 from MYR7.13. Shares are unchanged at MYR7.23. (yingxian.wong@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 29, 2024 20:12 ET (01:12 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IHH Healthcare's Earnings Outlook Remains Attractive -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIHH Healthcare's Earnings Outlook Remains Attractive -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-30 09:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0112 GMT - IHH Healthcare's earnings outlook may remain attractive amid rising demand and revenue intensity, particularly in the Indian and Malaysian markets, as key growth drivers, Maybank IB analysts Yin Shao Yang and Nur Natasha Ariza say in a note. Despite the stock's over 20% year-to-date share price gains, valuations indicate potential for a re-rating as IHH pursues both organic and strategic inorganic expansion, they add. The analysts project a 13% compound annual growth rate in three-year forward revenue and Ebitda for IHH. Maybank resumes coverage on IHH with a buy rating and raises its target price to MYR7.97 from MYR7.13. Shares are unchanged at MYR7.23. (yingxian.wong@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 29, 2024 20:12 ET (01:12 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"Q0F.SI","symbol_name":"IHH医疗保健集团","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2495551013","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2495551013","pubTimestamp":1735521120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0112 GMT - IHH Healthcare's earnings outlook may remain attractive amid rising demand and revenue intensity, particularly in the Indian and Malaysian markets, as key growth drivers, Maybank IB analysts Yin Shao Yang and Nur Natasha Ariza say in a note. Despite the stock's over 20% year-to-date share price gains, valuations indicate potential for a re-rating as IHH pursues both organic and strategic inorganic expansion, they add. The analysts project a 13% compound annual growth rate in three-year forward revenue and Ebitda for IHH. Maybank resumes coverage on IHH with a buy rating and raises its target price to MYR7.97 from MYR7.13. Shares are unchanged at MYR7.23. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"Q0F.SI":"IHH医疗保健集团","HCSG":"Healthcare Svcs Group Inc"},"translate_title":"IHH Healthcare的盈利前景仍然有吸引力——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"Q0F.SI":0.9,"HCSG":1},"content_text":"0112 GMT - IHH Healthcare's earnings outlook may remain attractive amid rising demand and revenue intensity, particularly in the Indian and Malaysian markets, as key growth drivers, Maybank IB analysts Yin Shao Yang and Nur Natasha Ariza say in a note. Despite the stock's over 20% year-to-date share price gains, valuations indicate potential for a re-rating as IHH pursues both organic and strategic inorganic expansion, they add. The analysts project a 13% compound annual growth rate in three-year forward revenue and Ebitda for IHH. Maybank resumes coverage on IHH with a buy rating and raises its target price to MYR7.97 from MYR7.13. Shares are unchanged at MYR7.23. (yingxian.wong@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 29, 2024 20:12 ET (01:12 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}